Skip to content

Bladder cancer risk group calculator

The TURBT report in the European guideline table, the chance of progression in each group and what changes in treatment.

Dr. Petronio Melo, urologistA reference in robotic surgery for kidney and bladder tumors
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 20, 2026
Book a consultation
Drawing of four windows showing the bladder wall in cross-section, side by side, above a band that goes from light blue to dark blue. In the first, a small tumour attached to the inner lining; in the second, two tumours; in the third, a larger tumour with a flat area of carcinoma in situ next to it; in the fourth, a tumour that grows down into the layer just below the lining, without reaching the muscle
On this page

Quick answer

The risk group of a bladder cancer that does not invade the muscle comes from the TURBT report: the stage, the grade, carcinoma in situ, the number and size of the tumours, your age and whether this is the first tumour or a recurrence. In the 2026 European guideline table, the groups are low, intermediate, high and very high.1 In the study that created the groups, the chance of progression at 5 years ranged from less than 1% in the low-risk group to more than 40% in the very high-risk group.3 The group guides BCG, chemotherapy into the bladder and the conversation about cystectomy, and the calculator result is something to bring to your consultation.

Find your risk group

You need the pathology report from the TURBT and the description of the operation or the cystoscopy, which usually gives the number and size of the tumours. The calculation applies to tumours that do not invade the muscle (Ta, T1 or carcinoma in situ).

Your answers stay in your browser. Nothing is sent, stored or saved in cookies, and everything is cleared when you close the page.

Is this the first tumour or has it come back?A recurrence is a tumour that appears again after a previous TURBT.
Stage in the TURBT reportTa stays in the inner lining. T1 reaches the layer just below it (lamina propria), without reaching the muscle.
Grade in the reportOne of the two systems is enough. If the report gives both, choose either. Low grade includes PUNLMP.
Does the report mention carcinoma in situ (CIS) together with the tumour?CIS is a flat lesion of the inner lining of the bladder.
How many tumours were removed at the TURBT?
Was the largest tumour more than 3 cm?The size is usually in the cystoscopy, TURBT or imaging report.
Age
Does the report mention any of these findings?Tick any that the report mentions. If it mentions none, leave them blank.

Result

Fill in the report details, then tap Show my risk group.

The calculation follows table 6.2 of the 2026 European guideline. One of the two grading systems is enough, either WHO 2004/2016 or WHO 1973. If the report gives both, choose either. If the tumour has already invaded the muscle (T2 or higher), the table does not apply, and the page on advanced bladder cancer explains the next steps.

The details in the calculation

  • Stage: Ta stays in the inner lining of the bladder. T1 reaches the layer just below it, the lamina propria, without reaching the muscle. The page is a bladder tumour serious? explains the layers.
  • Grade: in the WHO 2004/2016 system, the tumour is low grade or high grade, and low grade includes PUNLMP. In the 1973 system, it is G1, G2 or G3. The table accepts either.1
  • Carcinoma in situ (CIS): a flat lesion of the inner lining. Together with a tumour, it pushes the case into high or very high risk. On its own, with no papillary tumour, it counts as high risk.1
  • The three clinical factors: age over 70, more than one tumour and a tumour larger than 3 cm. Each one adds to the count.1
  • First tumour or recurrence: a recurrence is never low risk and goes to the group set by the other factors.1
  • Findings that go straight to very high risk: carcinoma in situ in the prostatic urethra, lymphovascular invasion and the micropapillary, plasmacytoid, sarcomatoid, nested and neuroendocrine subtypes.1

The European guideline table

This is the table the calculator uses, from the 2026 European guideline, which reproduces the 2021 groups from the Sylvester study:1,3

GroupHow it is defined
LowFirst tumour, single, Ta or T1 low grade or G1, up to 3 cm, no CIS, age 70 or younger. Or first tumour Ta low grade or G1, no CIS, with at most one of the three clinical factors
IntermediateNo CIS and not in any of the other groups
HighAny T1 high grade or G3 without CIS; any case with CIS; Ta low grade or G2, or T1 G1, with all three factors; Ta high grade or G3, or T1 low grade, with at least two factors; T1 G2 with at least one factor. Always excluding very high-risk cases
Very highTa high grade or G3 with CIS and all three factors; T1 G2 with CIS and at least two factors; T1 high grade or G3 with CIS and at least one factor; T1 high grade or G3 without CIS with all three factors. Also CIS in the prostatic urethra, lymphovascular invasion and aggressive subtypes

The three clinical factors are age over 70, more than one tumour and a tumour larger than 3 cm. An example: a first, single, small Ta low-grade tumour in a 75-year-old stays low risk, because it adds only one factor. If there were two tumours, the case would move to intermediate risk.

The chance of progression in each group

Progression here means the tumour invading the muscle or spreading further. Table 6.3 of the guideline gives the chance in each group, with one row for each grading system:1

Group1 year5 years10 years
Low0.06% (WHO 2004/2016) · 0.12% (WHO 1973)0.93% · 0.57%3.7% · 3.0%
Intermediate1.0% · 0.65%4.9% · 3.6%8.5% · 7.4%
High3.5% · 3.8%9.6% · 11%14% · 14%
Very high16% · 20%40% · 44%53% · 59%

In each cell, the first number is for the WHO 2004/2016 grading system and the second for WHO 1973. These figures come from patients who did not have BCG soon after the TURBT.1 The guideline itself notes that two studies, with 529 and 1,268 BCG-treated patients, found much lower progression in the high and very high-risk groups, and that a review also found the 2021 model overestimates progression.1 For patients who have BCG in the high and very high-risk groups, the table tends to show a higher risk than those studies found.

What the guideline recommends for each group

  • Low risk: follow-up is with cystoscopies. The first is 3 months after the TURBT and, if it is normal, the next is 9 months later, then one a year for 5 years.4
  • Intermediate risk: chemotherapy into the bladder is a reasonable first option for most patients, and 1 year of BCG, with induction and courses at 3, 6 and 12 months, is the alternative. The choice takes into account each patient's risk and the side effects of each treatment.2 The page on BCG for the bladder explains the instillations.
  • High risk: BCG into the bladder for 1 to 3 years, with immediate removal of the bladder, radical cystectomy, discussed with the patient.2
  • Very high risk: radical cystectomy, or BCG for 1 to 3 years, mainly for those who do not want or are not fit for surgery.2

In 2026, the guideline began recommending a discussion about adding sasanlimab or durvalumab to BCG with maintenance in selected high and very high-risk patients who have not had BCG before.2 In the intermediate, high and very high-risk groups, check cystoscopies are also more frequent, and the page is a bladder tumour serious? gives the schedule for each.

What the table does not show

The 2021 groups came from the data of 3,401 patients with a first tumour, treated with TURBT with or without chemotherapy into the bladder. The study itself lists as limitations the retrospective data collection and the lack of central pathology review.3 The model did not include carcinoma in situ on its own, carcinoma in situ in the prostatic urethra, recurrences, subtypes or lymphovascular invasion. For these cases, the guideline sets the group based on the literature, and the progression table does not apply.1

The guideline recommends finding the group with the official EAU calculator at nmibc.net.1,5 It follows the same table, with one small difference in size: the guideline refers to a tumour larger than 3 cm, and the official calculator asks whether it is 3 cm or more. And some things no table measures, such as the quality of the TURBT, each patient's health and their preferences. That is why the calculator gives the group and what the guideline recommends, but does not decide the treatment.

My approach

When the ultrasound or CT already shows a clear lesion in the bladder, I go straight to TURBT. In my practice, it is done under general anaesthesia, and the pathology result is ready in about 1 week. I explain that result and the risk group carefully at the follow-up visit, because they are what decide whether BCG is needed, and the decision is made together with the patient.

When BCG is recommended, I advise starting 6 to 8 weeks after the TURBT. The European guideline only rules out starting in the first 2 weeks. For the maintenance schedule, I follow the European guideline, and the instillations are given in hospital.

Send your case

If you have had a TURBT and would like my opinion on the report before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

How do I find out the risk group of my bladder cancer?

In the European guideline, the risk group of a tumour that does not invade the muscle comes from the TURBT report and a few clinical details: the stage (Ta or T1), the grade, whether there is carcinoma in situ, the number of tumours, the size of the largest one, your age and whether this is the first tumour or a recurrence. The groups are low, intermediate, high and very high.1,3 The calculator on this page works this out.

What is the chance of a bladder tumour progressing in each group?

In the study that created the 2021 groups, with 3,401 patients treated with TURBT with or without chemotherapy into the bladder, the chance of progression at 5 years ranged from less than 1% in the low-risk group to more than 40% in the very high-risk group.3 At 10 years, the guideline table gives 3.0% to 3.7% for low risk, 7.4% to 8.5% for intermediate, 14% for high and 53% to 59% for very high.1 These figures come from patients who did not have BCG soon after the TURBT.

What puts a tumour in the very high-risk group?

In the 2026 table, very high risk includes high-grade (or G3) tumours and T1 G2 tumours that come with carcinoma in situ and add clinical factors, such as age over 70, more than one tumour or a tumour larger than 3 cm. A T1 high-grade tumour without carcinoma in situ is included when it has all three factors. It also includes carcinoma in situ in the prostatic urethra, lymphovascular invasion and aggressive subtypes, such as micropapillary and plasmacytoid.1

Can a bladder tumour that has come back be low risk?

No. The European guideline places a recurrence in the intermediate, high or very high-risk group, according to the other factors, and never in the low-risk group.1 The progression table does not apply to recurrences either, because the study behind it only included first tumours.1,3

Do low-risk patients need BCG?

In the European guideline, BCG appears in the intermediate, high and very high-risk groups. For low risk, follow-up is with check cystoscopies: the first 3 months after the TURBT and, if it is normal, another 9 months later and then one a year for 5 years.2,4

Does the official EAU calculator give the same result?

The guideline recommends finding the group with the EAU's own calculator at nmibc.net.1,5 This page follows the 2026 guideline table. There is one small difference in size: the guideline refers to a tumour larger than 3 cm, and the official calculator asks whether it is 3 cm or more. Only a tumour of exactly 3 cm can fall into different groups.

Who assesses bladder cancer in São Paulo?

I see patients with bladder cancer in São Paulo, from TURBT to robotic cystectomy. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275, a reference in robotic surgery for kidney and bladder tumors. I hold a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. At the consultation, I review the TURBT report and explain the risk group and what the guideline and the studies show for it. My office is in Vila Mariana, and the first consultation can be in person or online, in English.

References

  1. EAU Guidelines on Non-muscle-invasive Bladder Cancer: predicting disease recurrence and progression (tables 6.2 and 6.3). European Association of Urology; 2026. EAU
  2. EAU Guidelines on Non-muscle-invasive Bladder Cancer: disease management. European Association of Urology; 2026. EAU
  3. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-488. PubMed
  4. EAU Guidelines on Non-muscle-invasive Bladder Cancer: follow-up. European Association of Urology; 2026. EAU
  5. European Association of Urology. EAU NMIBC 2021 Risk Calculator (official risk group calculator). EAU

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides